Skip to main content
. Author manuscript; available in PMC: 2015 Aug 17.
Published in final edited form as: Mol Ther. 2008 Jan 29;16(3):580–589. doi: 10.1038/sj.mt.6300404

Figure 2. Sleeping Beauty-engineered T cells specifically kill CD19+ leukemia and lymphoma cells.

Figure 2

(a) Cytotoxicity against CD19+ target cells shown by engineered PBL from two donors (PBL1 and PBL2). (b) Expression of CD19 on K562 transfectants. (c) Cytotoxicity shown by the engineered PBL against K562 transfectants. (d) CD19 specificity of the engineered umbilical cord blood (UCB) T cells, (e) Engineered T cell killing of target cells inhibited by the perforin pathway inhibitors. Similar results were obtained in at least three independent assays. EGTA, ethylene glycol tetraacetic acid; E/T ratio, effector/target ratio; GFP, green fluorescent protein.